Suven Life Sciences Limited has made a significant advancement in the fight against depression, announcing positive results from a Phase-2a proof-of-concept study involving Ropanicant (SUVN-911). The drug, tested for its efficacy in treating moderate to severe Major Depressive Disorder (MDD), showed rapid improvement in depressive symptoms within the first week of treatment. This development marks […]
Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful completion of its Phase-2 proof-of-concept study for samelisant. This novel medication was tested for its efficacy in reducing excessive daytime sleepiness (EDS) among adult patients with narcolepsy, both with and without cataplexy. The study reached its primary […]
Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to evaluate the safety and efficacy of samelisant in adult narcolepsy patients, with and without cataplexy in the US and Canada. The Indian clinical-stage biopharmaceutical company, which specializes in central nervous system (CNS) disorder therapies, anticipates releasing the […]
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression in Alzheimer’s type dementias. The Indian biopharma company expects to enroll patients from mid-September. Masupirdine is a selective, brain penetrant and orally active, chemical entity. Its late-stage study to be […]